Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th
NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq:IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day, taking place November 14th-15th, 2022.
Related news for (IMVT)
- Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025
- Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
- Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
- Immunovant Reports Financial Results for the Quarter Ended December 31, 2024
- Immunovant Announces $450 Million Private Placement